- Home
- NSRX vs FORA Comparison
NSRX vs FORA Comparison
Compare NSRX & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSRX | FORA |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.4M | 69.4M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | NSRX | FORA |
|---|---|---|
| Price | $7.75 | $2.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $20.50 | N/A |
| AVG Volume (30 Days) | 8.7K | ★ 28.5K |
| Earning Date | 02-15-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $28,106,911.00 |
| Revenue This Year | N/A | $47.82 |
| Revenue Next Year | N/A | $10.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 37.47 |
| 52 Week Low | $5.90 | $1.64 |
| 52 Week High | $9.99 | $4.03 |
Technical Indicators
Market Signals| Indicator | NSRX | FORA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 40.12 |
| Support Level | N/A | $2.06 |
| Resistance Level | N/A | $2.16 |
| Average True Range (ATR) | 0.00 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 34.57 |
Price Performance
Historical ComparisonAbout NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.